Taiwan - Delayed Quote TWD

PharmaEssentia Corporation (6446.TW)

1,245.00 +20.00 (+1.63%)

As of 10:40:17 AM GMT+8. Market Open.

 All 
 News 
 Earnings Calls 
 Press Releases 
 SEC Filings 

Ropeg Secures ET Approvals Across Asia and the U.S., Highlighting Treatment Access Gap in Europe

Business Wire 15h ago

6446.TW
+1.63%
6446
Ropeg Advances Essential Thrombocythemia Treatment Worldwide as European Patients Await Access

Business Wire 15h ago

6446.TW
+1.63%
6446
PharmaEssentia’s Ropeg Expands Global ET Approvals While Europe Awaits Regulatory Clearance

Business Wire 16h ago

6446.TW
+1.63%
6446
Ropeg Wins ET Approvals Across Major Markets as European Patients Await Expanded Access

Business Wire 16h ago

6446.TW
+1.63%
6446
Ropeg Gains ET Approvals in Major Global Markets as European Patients Await Access

Business Wire 16h ago

6446.TW
+1.63%
6446
PharmaEssentia to Participate in Upcoming Jefferies and Citi Healthcare Conferences

Business Wire 1d ago

6446.TW
+1.63%
6446
PharmaEssentia to Present Early-Stage Pipeline Data at the Society for Immunotherapy of Cancer (SITC) Annual Meeting, Highlighting Immuno-Oncology Approaches for Solid Tumors

Business Wire 8d ago

6446.TW
+1.63%
6446
PharmaEssentia to Present Data at 18th International Congress on Myeloproliferative Neoplasms Highlighting Unmet Need with Current Therapies and Real-World Use of BESREMi® in Essential Thrombocythemia and Polycythemia Vera

Business Wire 15d ago

6446.TW
+1.63%
6446
From PV to ET to PMF, PharmaEssentia Has Come A Long Way in Fighting Diseases

Business Wire 18d ago

6446.TW
+1.63%
6446
From Taiwan to the World: PharmaEssentia Expands Global Reach With New Drug Approvals, Overseas Investments

Business Wire 18d ago

6446.TW
+1.63%
6446
From Taiwan to the World: PharmaEssentia Builds a Scientist-Led, Fully Integrated Global Biopharmaceutical Company with Patients at Its Core

Business Wire 18d ago

6446.TW
+1.63%
6446
From Taiwan to the World: PharmaEssentia Expands Global Reach With New Drug Approvals, Overseas Investments

Business Wire 18d ago

6446.TW
+1.63%
6446

Performance Overview

Return	6446.TW	TSEC CAPITALIZATION WEIGHTED ST (^TWII)
YTD	+189.43%	+49.52%
1-Year	+173.16%	+52.84%
3-Year	+343.66%	+162.35%

U.S. markets closed

PharmaEssentia Corporation (6446.TW)

Ropeg Secures ET Approvals Across Asia and the U.S., Highlighting Treatment Access Gap in Europe

Ropeg Advances Essential Thrombocythemia Treatment Worldwide as European Patients Await Access

PharmaEssentia’s Ropeg Expands Global ET Approvals While Europe Awaits Regulatory Clearance

Ropeg Wins ET Approvals Across Major Markets as European Patients Await Expanded Access

Ropeg Gains ET Approvals in Major Global Markets as European Patients Await Access

PharmaEssentia to Participate in Upcoming Jefferies and Citi Healthcare Conferences

PharmaEssentia to Present Early-Stage Pipeline Data at the Society for Immunotherapy of Cancer (SITC) Annual Meeting, Highlighting Immuno-Oncology Approaches for Solid Tumors

PharmaEssentia to Present Data at 18th International Congress on Myeloproliferative Neoplasms Highlighting Unmet Need with Current Therapies and Real-World Use of BESREMi® in Essential Thrombocythemia and Polycythemia Vera

From PV to ET to PMF, PharmaEssentia Has Come A Long Way in Fighting Diseases

From Taiwan to the World: PharmaEssentia Expands Global Reach With New Drug Approvals, Overseas Investments

From Taiwan to the World: PharmaEssentia Builds a Scientist-Led, Fully Integrated Global Biopharmaceutical Company with Patients at Its Core

From Taiwan to the World: PharmaEssentia Expands Global Reach With New Drug Approvals, Overseas Investments